PerkinElmer will provide access to Predictive Diagnostics’s Biomarker Amplification Filter technology customized for PerkinElmer’s prOTOF 2000 MALDI-TOF, PerkinElmer said this week. PerkinElmer will offer PDI’s BAMF Technology services to pharmaceutical companies and research institutions, the company added. PDI’s BAMF Technology is a suite of in silico “machine-learning technologies” and informatics tools that use a “simple” blood test for the discovery of biomarker fingerprints to diagnose diseases using high-resolution mass spectrometry data, said PerkinElmer. The technology is intended for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases, the company added.